In addition, we show that our moleculesinduce the downregulation of oncogenic drivers of NMC, as demonstratedfor MYC and TP63. Overall, thiswork expands the set of available dual BET/HDAC inhibitors for cancertherapy and provides a basis for future translational studies in differentcancer types. This evidence concerns the gene TP63 and nut midline carcinoma.